Skip to main content
. 2021 Mar 27;22(7):3464. doi: 10.3390/ijms22073464

Figure 1.

Figure 1

PI3K inhibitors: pan, isoform-specific and dual PI3K/mTOR inhibitors to treat patients with different cancers (created with Biorender; www.biorender.com accessed on 20 March 2021).